Indeed, the tumorigenic immune dysfunction appeared to be reversed by anti-PD-1/PD-L1 treatment in a retrospective analysis conducted on 976 advanced cancer patients stratified according to BMI. This evidence concerns the gene PDCD1 and cancer.